MSN Laboratories Private Limited , INDIA - search results

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

jedoxred 250 (deferasirox dispersible tablets 250mg)

dr. reddy`s laboratories malaysia sdn. bhd. - deferasirox -

United States - English - NLM (National Library of Medicine)

decitabine injection, powder, lyophilized, for solution

msn laboratories private limited - decitabine (unii: 776b62cq27) (decitabine - unii:776b62cq27) - decitabine for injection is indicated for treatment of adult patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups. none. risk summary based on findings from human data, animal studies, and the mechanism of action, decitabine can cause fetal harm when administered to a pregnant woman [ see clinical pharmacology (12.1) and nonclinical toxicology (13.1)]. limited published data on decitabine use throughout the first trimester during pregnancy describe adverse developmental outcomes including major birth defects (structural abnormalities). in animal reproduction studies, administration of decitabine to pregnant mice and

United States - English - NLM (National Library of Medicine)

febuxostat tablet, film coated

msn laboratories private limited - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia. febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adve

United States - English - NLM (National Library of Medicine)

thiotepa injection, powder, for solution

msn laboratories private limited - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection is indicated for treatment of adenocarcinoma of the breast or ovary. thiotepa for injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. thiotepa for injection is indicated for treatment of superficial papillary carcinoma of the urinary bladder. pediatric use information is approved for adienne sa 's tepadina (thiotepa) for injection. however, due to adienne sa 's marketing exclusivity rights, the drug product is not labeled with that information. thiotepa for injection is contraindicated in: - patients with severe hypersensitivity to thiotepa [see warnings and precautions (5.2)] - concomitant use with live or attenuated vaccines [see warnings and precautions (5.4)] risk summary thiotepa can cause fetal harm when administered to a pregnant woman based on findings from animals and the drug’s mechanism of action [see clinical pharmacology (12.1)] . limited available data with thiotepa use in pr